Results 251 to 260 of about 16,658,609 (280)
JAMA, 2019 With chemotherapy and radiation being the most common forms of cancer treatment, some cancer cells are able to develop resistance and persist in the body.
Caron, Jacobson +2 more
core +6 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
CAR T-cells for cancer therapy
Biotechnology and Genetic Engineering Reviews, 2017Chimeric antigen receptor (CAR) T-cells are redirected T-cells that can recognize cancer antigens in a major histocompatibility complex (MHC)-independent fashion. A typical CAR is comprised of two main functional domains: an extracellular antigen recognition domain, called a single-chain variable fragment (scFv), and an intracellular signaling domain ...
Niaz, Muhammad, Qinwen, Mao, Haibin, Xia
openaire +2 more sources
Journal of Population Therapeutics and Clinical Pharmacology
There is rising interest in CAR-T therapy as a potential treatment of non-small cell lung cancer (NSCLC) that comprises about 85% of all lung cancer and has a high mortality rate. This is a new technology whereby T cells are engineered to attack certain tumor-specific antigens.
Dr. Renuka . +2 more
+4 more sources
There is rising interest in CAR-T therapy as a potential treatment of non-small cell lung cancer (NSCLC) that comprises about 85% of all lung cancer and has a high mortality rate. This is a new technology whereby T cells are engineered to attack certain tumor-specific antigens.
Dr. Renuka . +2 more
+4 more sources
CAR T-cell therapy for gliomas
Current Opinion in NeurologyPurpose of review To review the landscape of chimeric antigen receptor T-cell (CAR T) therapy for gliomas as seen in recently published trials and discuss on-going challenges with new cancer immunotherapy treatments. Recent findings Given how CAR T therapy has revolutionized the ...
Kun-Wei, Song, Brian J, Scott
openaire +2 more sources
CAR-T cell therapy and infection: a review
Expert Review of Anti-infective Therapy, 2020Introduction: Chimeric antigen receptor T-cell therapy (CAR-T cell therapy) is a novel immunotherapy with promising results in the treatment of relapsed or refractory B cell malignancies. Patients undergoing CAR-T cell therapy are at increased risk of infection due to prior immunosuppression, lymphodepleting chemotherapy, treatment of unique toxicities
Olivia Bupha-Intr +5 more
openaire +2 more sources
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Ca-A Cancer Journal for Clinicians, 2022Alexander Shimabukuro-Vornhagen +2 more
exaly
CAR T-cell therapy for B-cell lymphoma
Current Problems in Cancer, 2022Samantha Jaglowski +2 more
exaly
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
Annals of Oncology, 2021Karin Jordan +2 more
exaly